Company news

Zymeworks Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer

November 29, 2020

Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer

November 18, 2020

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer

November 15, 2020

Zymeworks Reports 2020 Third Quarter Financial Results

November 2, 2020

Zymeworks Reports 2020 Second Quarter Financial Results

August 4, 2020

Zymeworks Announces New Multispecific Antibody Collaboration with Merck

July 7, 2020

Zymeworks Announces Corporate Update Webcast and Conference Call

June 29, 2020

Zymeworks Reports 2020 First Quarter Financial Results

May 6, 2020

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene

March 31, 2020

Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors

March 15, 2020

Zymeworks Reports 2019 Year-End Financial Results

March 1, 2020

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Over-Allotment Option to Purchase Additional Shares

January 26, 2020

Zymeworks Announces Pricing of $279.0 Million Public Offering

January 21, 2020

Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

January 20, 2020

Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities

January 12, 2020

Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)

January 11, 2020

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

November 21, 2019

Zymeworks Announces Selection of ZW25 Abstract for Mini Oral Presentation at the European Society for Medical Oncology Asia (ESMO Asia) Congress

November 17, 2019

Zymeworks Files Automatic Shelf Registration Statement and Enters into At-The-Market Equity Offering Sales Agreement

November 4, 2019

← Newer news releases

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.